Incyte Shares Surge on Strong Revenue Performance and Pipeline Progress

The biotechnology firm Incyte concluded its 2025 fiscal year with robust momentum, surpassing its own product revenue forecasts. While flagship products delivered impressive growth, investor focus is shifting to the company's development pipeline and its capacity to offset upcoming patent expirations.

Incyte reported a significant 28% year-over-year increase in fourth-quarter revenue, reaching $1.51 billion. For the full year 2025, total revenue climbed to $5.14 billion, marking a 21% gain. A central component of this success was the performance of Jakafi, which generated $3.1 billion in product revenue, an 11% annual increase. Looking ahead, management has provided product revenue guidance for 2026 in a range of $4.77 billion to $4.94 billion.

Dual Growth Engines and Portfolio Expansion

The company’s revenue strength stems from two primary sources. Jakafi remains the cornerstone, accounting for approximately 60% of total annual revenue. Simultaneously, the topical cream Opzelura demonstrated explosive growth, with revenue soaring 33% to $678 million in 2025, solidifying its role as a major secondary growth driver.

Further diversification is underway with contributions from newer market entrants like Niktimvo and Zynyz. This broadening portfolio is a key strategic aim as Incyte prepares for a pivotal transition.

Should investors sell immediately? Or is it worth buying Incyte?

Strategic Pipeline Investments to Counter Patent Cliff

A critical challenge looms on the horizon: key patents for the original Jakafi formulation are set to begin expiring in 2028. Incyte's strategy to navigate this "patent cliff" involves aggressive pipeline development and lifecycle management for its key assets.

A major near-term milestone is the anticipated mid-2026 approval and launch of Jakafi XR, an extended-release version. To fuel its pipeline, the company ramped up research and development spending by 31% in Q4 2025 to $611.4 million. The development plan is ambitious, with 14 registration-enabling studies across seven distinct compounds expected to be active by the end of 2026.

The company anticipates seven clinical data readouts in 2026 that will shape its future market position. Significant regulatory milestones are also approaching. Following positive Phase 3 results, a supplemental Biologics License Application (sBLA) for Tafasitamab is slated for submission in the first half of 2026. Additionally, Incyte expects the U.S. Food and Drug Administration (FDA) to accept the New Drug Application for Povorcitinib in the first quarter. These events are crucial for reducing long-term dependence on Jakafi.

The coming years will test whether Incyte's substantial investment in its clinical pipeline can successfully generate new revenue streams to compensate for the impending loss of exclusivity for its most significant product.